Compare RMR & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMR | CADL |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 339.8M |
| IPO Year | N/A | 2021 |
| Metric | RMR | CADL |
|---|---|---|
| Price | $15.75 | $6.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 197.5K | ★ 960.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | ★ 11.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $196,824,000.00 | N/A |
| Revenue This Year | $301.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.48 | $4.25 |
| 52 Week High | $22.22 | $13.68 |
| Indicator | RMR | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 72.12 |
| Support Level | $14.85 | $5.39 |
| Resistance Level | $15.77 | $6.83 |
| Average True Range (ATR) | 0.36 | 0.36 |
| MACD | 0.05 | 0.22 |
| Stochastic Oscillator | 80.40 | 80.81 |
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.